Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vir Biotechnology Inc
(NQ:
VIR
)
8.810
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vir Biotechnology Inc
< Previous
1
2
3
Next >
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
June 26, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
June 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
May 29, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer
May 29, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Host 2024 Annual Meeting of Stockholders
May 23, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024
May 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024
May 21, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 02, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
April 30, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors
April 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
April 11, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
March 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences
February 23, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer
February 20, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Business Update and Report Fourth Quarter 2023 Financial Results on February 22, 2024
February 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Strategic Steps to Reduce Operating Expenses and Focus Investment on Areas with Highest Potential for Value Creation
December 13, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference
December 06, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
From laggards to leaders: Small caps on the rise
November 27, 2023
Despite large-cap dominance, signs suggest a shift to small-cap leadership. Valuations, positive Q3 results, and historical patterns point to potential gains.
Via
MarketBeat
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
November 13, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
November 10, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
November 08, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Appoints Jennifer Towne, Ph.D., as Executive Vice President and Chief Scientific Officer
October 30, 2023
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Conference
October 12, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
October 11, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023
October 05, 2023
From
Vir Biotechnology, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.